Jointown Pharmaceutical Group Co., Ltd (SHA: 600998)

Jointown Pharmaceutical Group Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	147,836	149,981	140,282	122,359	110,819	99,462
Other Revenue	117.55	158.54	142.16	48.09	40.49	34.6
Revenue	147,953	150,140	140,424	122,407	110,860	99,497
Revenue Growth (YoY)	-2.53%	6.92%	14.72%	10.42%	11.42%	14.19%
Cost of Revenue	136,512	138,140	129,560	112,636	100,981	90,826
Gross Profit	11,441	12,000	10,864	9,772	9,879	8,671
Selling, General & Admin	6,958	7,193	6,637	6,097	5,667	5,070
Research & Development	175.51	196.61	178.39	194.94	126.63	74.13
Other Operating Expenses	271.46	142.96	98.16	293.01	253.25	238.82
Operating Expenses	7,457	7,664	7,074	6,684	6,155	5,447
Operating Income	3,984	4,336	3,790	3,087	3,724	3,224
Interest Expense	-1,291	-1,318	-1,221	-1,145	-1,027	-1,240
Interest & Investment Income	267.7	255.17	490.63	310.74	288.54	245.3
Currency Exchange Gain (Loss)	3.29	-4.34	-17.05	-6.65	-1.53	0.1
Other Non Operating Income (Expenses)	-93.07	-173.82	-281.66	-151.72	-155.5	-117.58
EBT Excluding Unusual Items	2,871	3,095	2,760	2,094	2,828	2,111
Impairment of Goodwill	-	-1.18	-	-	-	-5.15
Gain (Loss) on Sale of Investments	-63.54	-78.4	1.44	1,235	1,052	-14.06
Gain (Loss) on Sale of Assets	3.96	5.11	45.67	6.72	258.03	7.22
Asset Writedown	-	-	-	-2.35	-0.69	-1.23
Other Unusual Items	15.96	-29.69	30.9	29.12	196.12	219.73
Pretax Income	2,828	2,991	2,838	3,363	4,334	2,317
Income Tax Expense	702.16	701.2	552.55	754.88	948.94	535.97
Earnings From Continuing Operations	2,125	2,290	2,286	2,608	3,385	1,781
Minority Interest in Earnings	-86.69	-115.62	-200.57	-160.05	-310.03	-54.93
Net Income	2,039	2,174	2,085	2,448	3,075	1,727
Net Income to Common	2,039	2,174	2,085	2,448	3,075	1,727
Net Income Growth	-5.57%	4.27%	-14.84%	-20.38%	78.10%	28.79%
Shares Outstanding (Basic)	4,931	5,099	5,274	5,187	5,172	5,465
Shares Outstanding (Diluted)	4,931	5,099	5,274	5,187	5,339	5,530
Shares Change (YoY)	-6.11%	-3.33%	1.68%	-2.84%	-3.47%	10.39%
EPS (Basic)	0.41	0.43	0.40	0.47	0.59	0.32
EPS (Diluted)	0.41	0.43	0.40	0.47	0.58	0.31
EPS Growth	0.58%	7.87%	-16.25%	-18.06%	84.50%	16.67%
Free Cash Flow	82.26	3,699	2,743	2,073	1,987	1,576
Free Cash Flow Per Share	0.02	0.73	0.52	0.40	0.37	0.28
Dividend Per Share	0.194	0.194	0.186	0.112	0.186	-
Dividend Growth	4.31%	4.31%	66.64%	-39.99%	-	-
Gross Margin	7.73%	7.99%	7.74%	7.98%	8.91%	8.71%
Operating Margin	2.69%	2.89%	2.70%	2.52%	3.36%	3.24%
Profit Margin	1.38%	1.45%	1.48%	2.00%	2.77%	1.74%
Free Cash Flow Margin	0.06%	2.46%	1.95%	1.69%	1.79%	1.58%
EBITDA	4,623	4,971	4,416	3,634	4,239	3,721
EBITDA Margin	3.12%	3.31%	3.14%	2.97%	3.82%	3.74%
D&A For EBITDA	638.35	634.96	626.41	547.21	514.33	497.06
EBIT	3,984	4,336	3,790	3,087	3,724	3,224
EBIT Margin	2.69%	2.89%	2.70%	2.52%	3.36%	3.24%
Effective Tax Rate	24.83%	23.44%	19.47%	22.44%	21.89%	23.13%
Revenue as Reported	147,953	150,140	140,424	122,407	110,860	99,497

Source: S&P Capital IQ. Standard template. Financial Sources.